Biopharmaceutical Contract Manufacturing to Reach Over $25 Billion by 2027. Contract manufacturing of live-attenuated Vaccines gaining popularity - Arizton

According to latest research report, biopharmaceutical contract manufacturing market to grow at a CAGR of over 14% during 2022-2027. Contract manufacturing services serve as a strategy for various companies ranging from big pharma players to small specialty entities. Major factors driving the demand for contract manufacturers include continuous cost-cutting efforts, decreased time to market, growing specialty firms that lack in-house manufacturing facilities, and an increase in outsourcing activities. In recent years, pricing pressures have been driving contract manufacturers to increase their operations in the market.

Click Here to Download the Free Sample Report: https://www.arizton.com/request-sample/3485

VENDORS INSIGHTS
The emergence of several start-ups and emerging players intensified the competition among vendors. Major vendors offering biopharmaceutical contract manufacturing services are present in the region of North America, including small, mid-sized, or even large companies. Europe and APAC contain a few larger players and several small and mid-sized vendors. Emerging economies, such as China, India, Brazil, and Mexico, are likely to offer significant growth opportunities for players in the biopharmaceutical contract manufacturing market. With increasing competition and the emergence of several companies, major vendors are getting more active and are focusing on more diverse contract manufacturing services as required by end-users.

MARKET SEGMENTATION
Product Type
• Finished Dosage Form (FDF)
• Active Pharmaceutical Ingredients (APIs)
Biologics
• Monoclonal Antibodies (mAbs)
• Vaccines
• Others
Expression System
• Mammalian
• Non-Mammalian
Scale of Operations
• Commercial
• Research (Clinical & Preclinical)
Company Size
• Large & Very Large Companies
• Small & Mid-Sized Companies
Geography
• Europe
o Germany
o UK
o France
o Switzerland
o Italy
o Spain
• APAC
o China
o Japan
o South Korea
o Australia
o India
• North America
o US
o Canada
• Latin America
o Brazil
o Mexico
• Middle East & Africa
o Saudi Arabia
o UAE
o South Africa
o Turkey

Key Vendors
• Boehringer Ingelheim
• Lonza
• Samsung Biologics

Key Companies
• AbbVie
• Catalent
• Emergent BioSolutions
• FUJIFILM
• Merck KGaA
• Pfizer
• Serum Institute of India
• WuXi Biologics

Other Prominent Vendors
• AGC Biologics
• Ajinomoto
• Albany Molecular Research (AMRI)
• Asymchem
• Biocon
• Cobra Biologics
• Charles River Laboratories
• Goodwin Biotechnology
• KBI Biopharma
• Sanofi
• Bavarian Nordic
• Wacker Biotech B.V
• Jubilant HollisterStier
• National Resilience
• Novasep
• Kemwell Biopharma
• Midas Pharma
• Alcami
• Cambrex
• Pharmaceutics International
• Singota Solutions
• Thermo Fisher Scientific
• Binexc
• Canton Biologics
• ChemPartner
• Cytovance Biologics

To know more: https://www.arizton.com/market-reports/biopharmaceutical-contract-manufacturing-market

ABOUT ARIZTON:  

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services. 

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports. 

Arizton Advisory and Intelligence
Call: +1-312-235-2040 
          +1 302 469 0707 

This release was published on openPR.